Combined PET/CT scanning with F-FDG is in current use in Hodgkin lymphoma.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
New tracers have been developed, such as F-choline in prostate cancer. Its use is under investigation in other solid tumors (eg, brain, liver, lung). We report a case of Hodgkin lymphoma incidentally detected on F-choline PET/CT in a prostate cancer patient and show a comparison with F-FDG PET/CT. F-choline PET/CT detected more lymph node lesions than the F-FDG PET/CT for this patient. Comparative studies of the 2 tracers might help fine-tune treatments and, in particular, delineate target zones in radiation therapy.
Goineau A, Colombié M, Rousseau C, Sadot-Lebouvier S, Supiot S. Are you the author?
Institut de Cancérologie de l'Ouest René Gauducheau, Saint-Herblain; and Centre de Recherche en Cancérologie de Nantes Angers, Inserm U892, Centre National de la Recherche Scientifique UMR 6299, University of Nantes, Nantes, France.
Reference: Clin Nucl Med. 2015 Aug;40(8):670-671.